ReviewMinerva endocrinologica2012
Pheochromocytoma: implications in tumorigenesis and the actual management.
Review in Minerva endocrinologica, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (Journal of translational medicine · 2023Article
- Management of Pheochromocytomas and Paragangliomas: A Case-Based Review of Clinical Aspects and Perspectives.Journal of clinical medicine · 2022Review
- Therapies targeting the signal pathways of pheochromocytoma and paraganglioma.OncoTargets and therapy · 2019Article
- Rare complications of neurofibromatosis 1 diagnosed incidentally in two children.Therapeutics and clinical risk management · 2018Article
- Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017Review
- Development of pheochromocytoma in ceramide synthase 2 null mice.Endocrine-related cancer · 2015Article
- Retroperitoneal paraganglioma presenting with pancytopenia: A rare case with rare manifestation.International journal of surgery case reports · 2015Article
- Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma.Endocrine-related cancer · 2014Review
- High-throughput screening for the identification of new therapeutic options for metastatic pheochromocytoma and paraganglioma.PloS one · 2014Article
- Tianeptine interferes with microtubule organization and hormone secretion of pheochromocytoma cells.Molecular and cellular endocrinology · 2013Article
- Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options.Current opinion in endocrinology, diabetes, and obesity · 2013Review
- Retroperitoneal paraganglioma presenting as a chest pain: a case report.Case reports in oncological medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Pheochromocytomas and paragangliomas are rare neuroendocrine catecholamine producing tumors with varied clinical presentations, biochemistries and genetic makeup. These features outline the complexity and the difficulties in studying and understanding the oncogenesis of these tumors. The study of families with genetically inherited mutations in pheochromocytoma susceptibility genes has greatly enhanced our understanding of the pathophysiology and mechanisms of oncogenesis of the disease, and consequently changed our clinical approach. Several molecular pathways and mutations in their important regulatory proteins have been identified. Such mutations are responsible for the dysregulation of metabolic pathways involved in oxygen and nutrient sensing, apoptosis regulation, cell proliferation, migration and invasion. The knowledge derived from the study of these pathways will be fundamental in the future clinical management of these patients. As a rare disease that often masks its clinical presentation, the diagnosis is frequently missed and a high level of suspicion is required. Management of this disease requires a multidisciplinary team approach and will be discussed along with advances in its treatment.
Indexed as
Identifiers
22691888PMC3409463W141354393What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.